EVOTEC

Founded in 1993, EVOTEC is a premier global platform company specializing in comprehensive drug discovery and development services. The firm leverages a sophisticated, data-driven multimodality platform to advance both first-in-class and best-in-class pharmaceutical products. By integrating cutting-edge technologies, EVOTEC supports a wide array of proprietary and partnered research initiatives across the global life sciences sector, focusing on oncology, antimicrobial agents, and precision medicine.

Operating with 1,000-5,000 employees, the company maintains a robust international footprint across 11 strategic locations. Their operational model is built upon high-throughput screening, advanced biomarker discovery, and integrated drug development services that span the entire value chain. Meet EVOTEC's team to learn about their leadership and organizational structure, which drives their collaborative approach to therapeutic innovation, clinical translation, and regulatory support. The company’s versatile infrastructure allows for seamless scaling from early-stage research to large-scale chemical development.

Publicly traded under the ticker NASDAQ: EVO, the company demonstrates significant market presence through strategic alliances and diverse funding sources, including major grants and private equity investments. With annual revenue reaching $886.1M, EVOTEC continues to scale its chemical development and manufacturing capabilities to meet global demand. Explore financial highlights for detailed metrics regarding their long-term growth, debt financing, and investment history. This financial stability supports their mission to make effective therapeutics globally available to patients in need.